Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (DE:5CV)
XETRA:5CV
Holding DE:5CV?
Track your performance easily
5CV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.11 - €5.71
Previous Close€2.66
Volume46.16K
Average Volume (3M)74.77K
Market Cap
€592.00M
Enterprise Value€231.38M
Total Cash (Recent Filing)$402.45M
Total Debt (Recent Filing)$41.82M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 12, 2024EPS Estimate
€1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding223,988,675
10 Day Avg. Volume78,360
30 Day Avg. Volume74,766
Standard Deviation0.25
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.15
Price to Sales (P/S)25.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.38
Enterprise Value/Gross Profit-3.28
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
€7.07Price Target Upside166.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CureVac News
PremiumCompany Announcements
CureVac’s Latest mRNA Advances Spark Investor Interest
PremiumCompany Announcements
CureVac Appoints New CFO to Drive Growth
PremiumCompany Announcements
CureVac’s CVGBM Shows Promise in Glioblastoma Study
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCureVac reported 2Q24 results, ending the quarter with €202.5M and receiving the €400M upfront from GSK for COVID-19/flu, bringing estimated pro forma cash to €602.5M.
Research And DevelopmentCVAC received a €10mm milestone after the Phase 1/2 avian influenza (H5N1) trial advanced into Phase 2.
Strategic FocusCVAC plans to focus on therapeutic opportunities in oncology and infectious diseases.
Bears Say
Executive DepartureThe announcement of the CFO's departure could lead to uncertainty in financial leadership and strategy.
Financial PerformanceCash resources were notably impacted by over €80 million due to ongoing obligations related to the first-generation COVID-19 vaccine, highlighting financial strain.
Workforce ReductionCVAC continues to work through a significant workforce reduction of approximately 30% by the end of the year, indicating potential operational challenges.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
0.08% Mutual Funds
0.04% Other Institutional Investors
98.67% Public Companies and
Individual Investors
5CV FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was €2.11 and its highest was €5.71 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Aug 15, 2024. The company reported -€0.32 earnings per share for the quarter, missing the consensus estimate of -€0.281 by -€0.039.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is €1.41.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of -€0.32 in its last earnings report, missing expectations of -€0.281. Following the earnings report the stock price went up 3.261%.
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at N/A.
---
CureVac Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.07 (166.11% Upside)
€7.07 (166.11% Upside)
Blogger Sentiment
Bearish
DE:5CV Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.17%
12-Months-Change
Fundamentals
Return on Equity
-54.12%
Trailing 12-Months
Asset Growth
-39.19%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
5CV Company Deck
---
5CV Earnings Call
Q4 2024
0:00 / 0:00
---
5CV Stock 12 Month Forecast
Average Price Target
€7.07
▲(166.11% Upside)
Technical Analysis
Best Analysts Covering 5CV
1 Year
1 Year Success Rate
1/24 ratings generated profit
1 Year Average Return
-38.70%
reiterated a buy rating 2 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 4.17% of your transactions generating a profit, with an average return of -38.70% per trade.
---